Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
0.5495
+0.0095 (1.76%)
Apr 6, 2026, 11:01 AM EDT - Market open
Galmed Pharmaceuticals Employees
As of December 31, 2024, Galmed Pharmaceuticals had 6 total employees, including 3 full-time and 3 part-time employees. The number of employees decreased by 2 or -25.00% compared to the previous year.
Employees
6
Change (1Y)
-2
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,718,167
Market Cap
3.62M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 6 | -2 | -25.00% | 3 | 3 |
| Dec 31, 2023 | 8 | -2 | -20.00% | 3 | 5 |
| Dec 31, 2022 | 10 | -14 | -58.33% | 4 | 6 |
| Dec 31, 2021 | 24 | 0 | - | 19 | 5 |
| Dec 31, 2020 | 24 | 3 | 14.29% | 18 | 6 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| GeoVax Labs | 17 |
| Silexion Therapeutics | 14 |
| VivoSim Labs | 14 |
| Azitra | 13 |
| Akari Therapeutics, | 9 |
| Alzamend Neuro | 6 |
| Enveric Biosciences | 6 |
| Indaptus Therapeutics | 5 |
GLMD News
- 5 days ago - Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 - PRNewsWire
- 2 months ago - Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification - PRNewsWire
- 4 months ago - Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting - PRNewsWire
- 4 months ago - Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - PRNewsWire
- 4 months ago - Galmed Issues CEO Letter to Shareholders - PRNewsWire
- 4 months ago - Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 4 months ago - Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine - PRNewsWire
- 5 months ago - Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro - PRNewsWire